Skip to main content
Equibles
CLDX logo

CLDX · Celldex Therapeutics, Inc.

Track CLDX — free

Use CLDX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CLDX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$41.95 -0.66 (-1.55%) At close · Aug 14
Market Cap
$3.29B
Shares
78.53M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$41.95 Open$42.23 Day$40.88–42.35 52W close$20.89–44.87 Avg vol 30d964K Short int7.6M · 9.7% float · 7.6d Short vol50% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Feb 28, 2028 Est · unconfirmed · in 80 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +38%
above
Price vs 50-day avg +15%
above
RSI (14) 62
neutral
MACD trend Positive
52-week position 88%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +19%
trailing
6-month return +72%
trailing
YTD return +54%
this year
Relative strength +59%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $36 › 200d $30 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +49 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.71% of float · ▼ -0.5% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
254 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Fair
Revenue growth +88%
Y/Y
EPS growth −59%
Y/Y
Free cash flow $-213.7M
Balance sheet $28.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −24%
past year
ATR 4.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+38% Bullish
Price vs 50-day avg
+15% Bullish
RSI (14)
62 Neutral
MACD trend
Positive Bullish
52-week position
88% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $36 › 200d $30 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +49 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.71% of float · ▼ -0.5% MoM · 7.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
254 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $21 Now $42 · 88% Range high $45
vs 200-day avg +38% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Shares outstanding 78.5M as of June 30, 2026 —
Countries in Phase 3 CSU program 43 EMBARQ-CSU1 and EMBARQ-CSU2 —
Patients enrolled in Phase 3 CSU program 1,939 EMBARQ-CSU1 and EMBARQ-CSU2 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLDX
Celldex Therapeutics, Inc.
this stock
$3.29B +54.5% +87.8% — 9.7%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
254
% held
108.5%
Net QoQ
+12.0M sh
Top holder
WELLINGTON MANAGEMENT GRO…
Held Float
View
Held by Funds
Fund positions
237
View
Short & Settlement
Short Interest Falling
Shares short
7.6M
Days to cover
7.6d
Change
-36.1K sh
View
Short Volume
Short vol %
50%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
673
Value
$24.8K
As of
Jul 2, 2026
View
Off-Exchange
Off-exchange %
44.2%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.5M
Net income (FY)
$-258.8M
EPS diluted
$-3.90
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
11
View
Proposed Sales
Value
$121.2K
Shares
4.2K
Filed
Dec 4, 2025
View
Earnings & Events
Earnings Calls
Last call
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
CLDX +0.6% +18.7% +72.5% +10.2% +54.5%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +0.2% +14.2% +58.7% +6.3% +40.6%
Key facts CIK 744218 CUSIP 15117B202 13F (30d) 245 filings 240 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)